Illustrative image – not actual.
Syngene International, a subsidiary of Biocon, plans to set up a multi-client, multi-product contract manufacturing plant at Mangalore special economic zone (MSEZ) at an investment of Rs 660 crore.
The plant at MSEZ will have the capacity to produce 500 kilo litres of molecules in the form of powder.
The molecules will be used in several disease areas like gastro intestinal disorders, oncology, cardio vascular, neuro sciences, diabetic and infectious diseases depending on the requirements of the client.
It would cater to global pharma giants in Japan, US, Europe, and North America.
The Mangaluru facility will be built on a 48 acre land and will be operational by fiscal year 2018 end. It will employ 500 persons. The required funds will be met through internal accruals and external borrowings.
More Project Info:
Active Pharmaceutical Ingredients (Mangalore) Project
